Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostic company leveraging microRNAs as biomarkers, announced that Amir Avniel, president and chief executive officer, will be presenting a corporate update at the Eighth Annual Needham and Company Biotechnology and Medical Technology Conference on Wednesday, June 10, 2009 at 8:30 a.m., (Eastern Daylight Time) at the New York Palace Hotel in New York City.

A live webcast of the presentation will be available by going to the investor relations section of www.rosettagenomics.com and clicking on the link to Live Webcasts. An archived replay will be available for a period of 30 days.

About Rosetta Genomics

Rosetta Genomics is a leading molecular diagnostics company developing and commercializing molecular diagnostic products based on its proprietary microRNAs. Rosetta Genomics is working to develop early detection cancer screening products, including a colon cancer screening test. Rosetta performs its commercial molecular diagnostics tests at Rosetta Genomics Laboratories in Philadelphia.

About MicroRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic and therapeutic strategy for many diseases.

Forward-Looking Statements

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the development of early detection cancer screening products, including Rosetta’s ability to successfully develop and commercialize a non-invasive colon cancer screening test by late 2009 or early 2010, if at all, and the sufficiency of Rosetta’s cash resources, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under “Key Information - Risk Factors” in Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2007 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law. Rosetta cannot guarantee that the performance suggested by data we released during the development process of a non-invasive colon cancer screening test will be identical to the performance of any test that we may successfully commercialize.

Rosetta Genomics
Ron Kamienchick, 646-509-1893
investors@rosettagenomics.com
or
Investor Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com